Gilead's $7.8B Arcellx Bet and Lenacapavir's Global Push Reshape the Company's Next Decade

Gilead Sciences is executing a two-pronged transformation: acquiring Arcellx to revive its flagging cell therapy business while rolling out lenacapavir — Science's 2024 Breakthrough of the Year — across sub-Saharan Africa. With $29.4B in TTM revenue and HIV growth of 6% YoY, the Biktarvy-powered cash machine is funding an aggressive oncology pivot.

GILD · Health Care · March 06, 2026

S&P 500 Position

Within Health Care — the S&P 500's second-largest sector — Gilead sits behind the mega-caps (UnitedHealth, Lilly, J&J, AbbVie, Merck, Abbott, Thermo Fisher, Amgen) but is a top-3 biotech pure-play alongside Amgen and Regeneron. Its closest competitive peers are AbbVie (immunology/oncology overlap), Merck (virology heritage), and Bristol-Myers Squibb (cell therapy competition). Vertex is the other large biotech in the index but operates in a different therapeutic space (cystic fibrosis, pain).

Index Weight: ~0.38% | Rank: Approximately #70-80 in the S&P 500 by market cap

Company Overview

Gilead is running one of the more interesting dual-track strategies in biopharma right now. Its HIV franchise — anchored by Biktarvy at $4B/quarter and over 52% U.S. treatment market share — continues to print money, while the newly launched Yeztugo (lenacapavir for PrEP) is opening an entirely new long-acting injectable prevention market. The twice-yearly injection showed near-complete protection against HIV infection in clinical trials, and Gilead is now negotiating voluntary licenses for domestic production in South Africa, the country with the world's highest HIV burden. Lenacapavir has already secured regulatory approvals in over a dozen countries since late 2025, with Gilead simultaneously developing a once-yearly formulation now in Phase 3. The oncology side is where the strategic risk — and upside — concentrates. Gilead announced the $7.8 billion acquisition of Arcellx in February 2026 to gain full control of anito-cel, a BCMA-directed CAR-T therapy for multiple myeloma with a PDUFA date of December 23, 2026. This deal eliminates profit-sharing obligations from the 2022 Kite-Arcellx collaboration and gives Gilead Arcellx's proprietary D-Domain CAR platform, which has implications for next-generation cell therapies and in vivo approaches. Cell therapy revenues declined 7% in 2025 and are guided down another 10% for 2026 due to competitive pressure from J&J/Legend's Carvykti — anito-cel is Gilead's bet to reverse that trajectory. Meanwhile, Gilead's pipeline has expanded beyond its traditional virology roots into inflammation (oral STAT6 program via LEO Pharma partnership), in vivo cell therapy (Interius BioTherapeutics acquisition), and oncology (Trodelvy in breast cancer, plus multiple bispecific antibody programs). The company guided FY2026 product sales of $29.6–30B and non-GAAP EPS of $8.45–8.85, with up to 10 potential launches through 2027 and no major loss-of-exclusivity events until 2036.

Products & Revenue

Gilead's revenue is overwhelmingly driven by HIV, which accounts for roughly 73% of total product sales. Biktarvy alone generates more than half of all revenue. The remaining portfolio splits across liver disease (Epclusa, Harvoni, the recently launched Livdelzi), oncology (Trodelvy ADC and Yescarta/Tecartus CAR-T via Kite), and the rapidly declining COVID-19 antiviral Veklury. The company's 2025 product sales totaled $28.9B, with base business (ex-Veklury) growing 4% to $28B.

HIV Treatment (Biktarvy, Genvoya, Odefsey, others) (~58%): Biktarvy is the dominant single-tablet regimen with 52%+ U.S. market share. Q4 2025 Biktarvy sales hit $4.0B (+5% YoY). Gilead is developing a bictegravir/lenacapavir combination tablet (ARTISTRY trials) as the next-generation treatment.

HIV Prevention (Descovy, Truvada, Yeztugo/Sunlenca) (~15%): Descovy PrEP sales surged 33% YoY to $819M in Q4. Yeztugo (lenacapavir injectable PrEP) contributed $96M in Q4 alone ($150M full-year 2025) in its first year, rapidly gaining share and expanding the addressable market.

Liver Disease (Epclusa, Harvoni, Vemlidy, Livdelzi) (~10%): Portfolio grew 17% YoY in Q4 2025 to $844M, powered by Livdelzi (seladelpar) achieving >50% market share in second-line PBC treatment in the U.S. Hepatitis franchise is mature but stable.

Cell Therapy / Kite (Yescarta, Tecartus) (~6%): CAR-T therapies for large B-cell lymphoma and mantle cell lymphoma. Revenue declining (~$1.8B in 2025, -7% YoY) due to in- and out-of-class competition. The pending Arcellx acquisition and anito-cel for multiple myeloma are positioned to reverse this trend.

Oncology — Trodelvy (~5%): Antibody-drug conjugate (sacituzumab govitecan) is the #1 treatment in second-line metastatic triple-negative breast cancer. Q4 sales of $384M (+8% QoQ). Expanding into additional breast cancer subtypes and other solid tumors.

Veklury (COVID-19) (~3%): Remdesivir for COVID-19 hospitalizations. Sales declined 37% YoY to $212M in Q4 2025 as hospitalization rates continue to fall. Expected to become immaterial over time.

Based on Gilead's Q4/FY2025 earnings release (February 2026) and supplementary data. Percentages are approximate based on full-year 2025 product sales of $28.9B.

Leadership

Daniel O'Day

CEO since 2019. Former CEO of Roche Pharmaceuticals, where he spent over 30 years rising through commercial and operational leadership roles across Europe and globally. O'Day holds a BS in Biology from Georgetown and an MBA from Columbia Business School. Under his leadership, Gilead has executed $30B+ in M&A (Immunomedics, Arcellx) and transformed from a virology-focused company into a diversified biopharma with major oncology and inflammation ambitions.

Flavius Martin, MD, Executive Vice President, Research: Oversees all discovery research and preclinical programs across therapeutic areas. Previously VP of Research Biology at Amgen (oncology, inflammation, cardiometabolic) and a scientist at Genentech. He is the architect of Gilead's AI-for-drug-discovery partnership strategy, including the Genesis Therapeutics and Terray Therapeutics collaborations.

Cindy Perettie, Executive Vice President, Kite: Runs Gilead's entire cell therapy business. Former CEO of Foundation Medicine and Head of Global Oncology Strategy at Roche. She is leading the Arcellx integration, the commercialization pipeline for anito-cel, and Kite's push into in vivo cell therapy via the Interius BioTherapeutics acquisition.

Jared Baeten, MD, PhD, Senior Vice President, Clinical Development, Virology Therapeutic Area Head: Professor at the University of Washington and a globally recognized HIV prevention researcher. He led clinical programs underpinning lenacapavir's approval, including the PURPOSE trials that established twice-yearly injectable PrEP. Now overseeing the once-yearly lenacapavir formulation trials and the bictegravir/lenacapavir combination development.

Dietmar Berger, MD, PhD, Chief Medical Officer: Joined in January 2025 from Sanofi (Global Head of Development) and Atara Biotherapeutics (EVP, R&D). Previously held medical affairs roles at Genentech, Bayer, and Amgen. Responsible for the company's clinical pipeline spanning HIV, oncology, inflammation, and liver disease.

Andrew Dickinson, Executive Vice President, Chief Financial Officer: Oversees global finance, corporate development, IT, operations, and strategy. Has orchestrated Gilead's capital allocation strategy including $4B in annual dividends, $1.9B in 2025 share repurchases, and the structuring of the $7.8B Arcellx deal.

The AI Angle

Partnering to AI-enable drug discovery pipelines

Gilead's AI strategy is built on a 'partner, don't build' model — leveraging external AI-native biotech platforms for drug discovery while investing heavily in internal data infrastructure. The two headline partnerships are with Genesis Therapeutics ($35M upfront, September 2024) and Terray Therapeutics (December 2024). Genesis brings its GEMS platform — integrating deep learning predictive models, molecular simulations, and generative AI (language models and diffusion models) — to generate and optimize small molecules for complex protein targets selected by Gilead. Terray's tNova platform combines ultra-high-throughput chemical experimentation with a generative AI-driven discovery engine, applying AI methods to an extensive library of quantitative structure-activity data. Both deals give Gilead exclusive development and commercialization rights to resulting compounds. Flavius Martin, Gilead's EVP of Research, has framed these as essential tools for tackling targets with limited training data — the hardest problem in computational drug discovery. On the infrastructure side, Gilead has moved 80% of its compute and storage workloads to AWS and operates an enterprise data platform built on a data mesh architecture with over 300 published internal data products. The company built an enterprise search tool using Amazon Kendra that centralized ~250,000 documents and 1TB of unstructured data from nine enterprise systems, yielding a claimed 25% increase in employee productivity within its Pharmaceutical Development and Manufacturing unit. Gilead also uses generative AI for target assessment — envisioning months-long reductions in the time needed to produce high-quality target assessment reports — and is exploring reuse of LLM architectures and LLMOps across the company. The operational AI layer is powered by Cognizant, which signed an $800M five-year service agreement in 2023 and expanded the partnership in January 2025 to deploy its Neuro AI generative AI platform across Gilead's business. This covers customer service automation, employee interaction optimization, manufacturing efficiency, and IT service transformation using generative AI within an agentic framework. CEO Daniel O'Day has publicly stated he envisions AI accelerating drug discovery and refining surrogate markers in oncology and autoimmune diseases. The risk for Gilead is the same as for every big pharma company playing the AI partnership game: the actual molecule-to-clinic translation remains unproven for AI-discovered compounds, and competitors like Novartis (>$1B deal with Generate:Biomedicines) and Recursion/Roche are investing at larger scale. Gilead's advantage is its proprietary clinical datasets — decades of HIV, HCV, and oncology trial data — and its willingness to move fast on integrating AI-generated leads into its existing therapeutic expertise. The company's strategy of multiple smaller, targeted partnerships rather than a single massive platform bet reduces integration risk but may limit the transformative upside.

Financial Snapshot

Revenue (TTM): $29.4B — TTM (ending Dec 2025) | Net Income: $8.5B net income

Margins: Gross ~87% (non-GAAP product), operating ~45% (non-GAAP, up from 30% prior year), net 28.9%

Gilead's financial trajectory inflected sharply in 2025. Non-GAAP operating income surged 55% to $13.2B and non-GAAP diluted EPS rose 77% to $8.15, partly driven by lower acquired IPR&D charges relative to 2024's heavy deal activity. The company generated $3.3B in operating cash flow in Q4 alone and returned 63% of free cash flow to shareholders through $4B in dividends and $1.9B in buybacks. The 3.8% dividend increase to $0.82/share quarterly signals continued confidence. FY2026 guidance of $29.6–30B in product sales and $8.45–8.85 non-GAAP EPS implies steady growth even while absorbing the Arcellx acquisition costs.

1-Year Performance

$145.14 as of March 5, 2026. The stock has surged over 48% in the past 12 months, dramatically outperforming both the S&P 500 (+12%) and the Health Care Select Sector SPDR (+6.5%).

The rally has been driven by three catalysts: the commercial success of lenacapavir/Yeztugo and its regulatory approvals across multiple countries, the strong Q4 2025 earnings beat ($7.93B revenue vs. $7.68B expected), and the strategic clarity provided by the Arcellx acquisition. The stock has pulled back ~8% from its all-time high as investors digest the $7.8B Arcellx price tag and the guided 10% decline in existing cell therapy revenues for 2026. With a beta of just 0.18, GILD remains a defensive anchor for healthcare portfolios.

Recent News

Fun Fact: Lenacapavir, the molecule behind Yeztugo, is the first-in-class HIV capsid inhibitor — it works by a completely novel mechanism, targeting multiple stages of the HIV lifecycle by interfering with the capsid protein shell that protects the virus's genetic material during replication. Its long-acting pharmacokinetics stem from the drug's extremely low aqueous solubility: once injected subcutaneously, it forms a depot that slowly releases over six months. The journal Science named it the 2024 Breakthrough of the Year — the first time a commercial pharmaceutical product received that distinction since the CRISPR-based gene therapy Casgevy shared the honor the year prior. Gilead is now testing a once-yearly intramuscular formulation that could reduce PrEP to a single annual injection.